at the very Core of it all … is Content!
Mexico City, 24 July 2018: Mundipharma has expanded its ophthalmology portfolio in Latin America by agreeing a new commercial partnership with NTC – an Italian pharmaceutical company with deep experience in research and development – for exclusive rights to license and distribute a range of ophthalmic medicines across the region. This builds on the …
SINGAPORE, June 6, 2018 /PRNewswire/ — Mundipharma has announced a licensing agreement with Korean biomedical firm, Genewel Co.Ltd, to market and distribute its GUARDIX-SG™ Surgical Adhesion Barrier portfolio across Southeast Asia. GUARDIX-SG™ is used in surgery as a biodegradable mechanical barrier, reducing abnormal internal scarring post surgery by separating the internal tissues and organs while they heal. …
SINGAPORE, May 28, 2018 /PRNewswire/ — Mundipharma CEO, Raman Singh, has been included in the 2nd Edition of Asia’s Greatest Leaders, which is published by AsiaOne and chosen by consumers and industry in a selection process reviewed by PricewaterhouseCoopers This follows an awards ceremony held at the Marina Bay Sands, Singapore in January, which was …
Singapore, 19 February 2018: Mundipharma has today announced the acquisition of specialist pharmaceutical company, Tolmar Australia Pty Limited, (“Tolmar”), including exclusive distribution rights for the oncology medication Eligard® (leuprorelin acetate) in Australia and New Zealand following several months of comprehensive due diligence and negotiation. The acquisition includes the oncology medications Eligard® and Bi-Eligard …
New Partnership builds on existing relationship BETADINE® branding to appear on medical team apparel and kit reinforcing Official Healthcare Product Partner status Enhanced digital brand presence to reach global consumer audience MANCHESTER, 21 August 2017: Mundipharma and English Premier League giants Manchester City have agreed to a new global partnership following an inaugural first season …